Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
EERP Maintains Buy on Virtualware With €8 Price Target

EERP Maintains Buy on Virtualware With €8 Price Target

BitgetBitget2026/10/28 06:55
  • European Equity Research Partners maintained its Buy rating on Virtualware with an €8 target price in an October 22, 2026, note.
  • Applying the same valuation method to 2027 estimated revenue of €11.52 million implies a €13.25 target price.
  • The current target uses 2026 estimated revenue of €7.29 million; EERP expects to roll the valuation base at full-year results.
  • EERP raised its 2027 revenue forecast by 60.5%; its EBITDA estimate increased to €3.35 million from €1.96 million.
  • The Spain-based research firm provides issuer-sponsored coverage commissioned by Virtualware.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virtualware 2007 SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280255OMX_____CNEWS_EN_GNW1001280258_en) on October 28, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear

Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

智通财经•2026/11/04 03:53

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs

AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.

智通财经•2026/11/04 02:51